A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
The following discussion of our business contains forward-looking statements that involve risks and uncertainties. When used in this report, the words “intend,” “anticipate,” “believe,” “estimate,” “plan” and “expect” and similar expressions as they relate to us are included to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements and are a result of certain factors, including those set forth under “Risk Factors” and elsewhere in this Annual Report on Form 10-K (“Form 10-K”). References throughout this Form 10-K to “Repligen Corporation”, “Repligen”, “we”, “us”, “our”, or the “Company” refer to Repligen Corporation and its subsidiaries, taken as a whole, unless the context otherwise indicates.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 738M | 738M | 634M | 632M | 802M | 671M |
| Net Income | 49M | 49M | -26M | 36M | 186M | 128M |
| EPS | $0.86 | $0.86 | $-0.46 | $0.63 | $3.24 | $2.24 |
| Free Cash Flow | 94M | 94M | 150M | 78M | 87M | 52M |
| ROIC | 1.9% | 2.3% | -1.0% | 2.4% | 9.6% | 7.9% |
| Gross Margin | 52.3% | 52.3% | 43.3% | 44.0% | 56.9% | 58.3% |
| Debt/Equity | 0.33 | 0.33 | 0.35 | 0.40 | 0.37 | 0.36 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 55M | 55M | -35M | 48M | 225M | 167M |
| Operating Margin | 7.5% | 7.5% | -5.5% | 7.5% | 28.0% | 24.9% |
| ROE | 2.3% | 2.4% | -1.3% | 1.8% | 9.7% | 7.3% |
| Shares Outstanding | 57M | 57M | 55M | 57M | 57M | 57M |
REPLIGEN CORP passes 3 of 9 quality checks, indicating weak fundamentals.
REPLIGEN CORP trades at 142.5x trailing earnings, compared to its 15-year median P/E of 50.6x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 73.5x vs a median of 73.0x. The company's 5-year average ROIC is 4.2% with a gross margin of 51.0%. At current prices, the estimated annualized return to fair value is +23.1%.
REPLIGEN CORP (RGEN) has a current P/E ratio of 142.5, compared to its historical median P/E of 50.6. The stock is currently considered Expensive based on its historical valuation range.
REPLIGEN CORP (RGEN) has a 5-year average return on invested capital (ROIC) of 4.2%. This is below average and may indicate limited pricing power.
REPLIGEN CORP (RGEN) has a market capitalization of $7.0B. It is classified as a mid-cap stock.
REPLIGEN CORP (RGEN) does not currently pay a regular dividend.
Based on historical P/E analysis, REPLIGEN CORP (RGEN) appears expensive. The current P/E of 142.5 is 182% above its historical median of 50.6. The estimated fair value CAGR (P/E method) is 1.9%.
REPLIGEN CORP (RGEN) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
REPLIGEN CORP (RGEN) reported annual revenue of $738 million in its most recent fiscal year, based on SEC EDGAR filings.
REPLIGEN CORP (RGEN) has a net profit margin of 6.6%. This is a modest margin.
REPLIGEN CORP (RGEN) generated $94 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
REPLIGEN CORP (RGEN) has a debt-to-equity ratio of 0.33. This indicates a conservatively financed balance sheet.
REPLIGEN CORP (RGEN) reported earnings per share (EPS) of $0.86 in its most recent fiscal year.
REPLIGEN CORP (RGEN) has a return on equity (ROE) of 2.4%. This indicates moderate shareholder returns.
REPLIGEN CORP (RGEN) has a 5-year average gross margin of 51.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for REPLIGEN CORP (RGEN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
REPLIGEN CORP (RGEN) has a book value per share of $37.04, based on its most recent annual SEC filing.